Performance | Financial Review Financial Review The financial performance for the full year The purpose of this Financial Review is Contents 2012 was dened by the significant revenue to provide a balanced and comprehensive 86 Introduction decline associated with the loss of exclusivity analysis of the financial performance of the 86 2012 Business background for several products, with revenue down business during 2012, the financial position and results overview 15% in constant currency terms.
as at the end of the year and the main 88 Measuring performance business factors and trends which could 2012 Spending discipline and restructuring affect the future financial performance 89 Results of operations benets only partially mitigated the impact of the business.
summary analysis of year of the revenue decline on Core profits to 31 December and margins, particularly as we remain All growth rates in this Financial Review are 91 Cash ow and liquidity committed to investment to drive future expressed at CER unless noted otherwise.
92 Financial position growth and value.
Core earnings per share, 94 Capitalisation and shareholder return 2012 Business background which benefited from the favourable impact 94 Future prospects and results overview of two tax related matters and the sale 2011 The business background is covered in of Nexium OTC rights, were down 9%.
95 Results of operations the Our industry section from page 16, the summary analysis of year Productivity and efficiency programmes Therapy Area Review from page 50 and to 31 December continue to deliver their target levels the Geographical Review from page 70, 96 Cash ow and liquidity of savings, providing the headroom and describes in detail the developments in 97 Financial position to invest behind key growth platforms both our products and geographical regions.
97 Revised Core financial measures and in progressing the pipeline.
Our cash 99 Financial risk management As described earlier in this Annual Report, generation remains strong, funding these 99 Critical accounting policies sales of our products are directly inuenced investments for future growth and value and estimates by medical need and are generally paid for 103 Sarbanes-Oxley Act Section 404 whilst providing $5.9 billion in net cash by health insurance schemes or national distributions to shareholders through net healthcare budgets.
Our operating results share repurchases of $2.2 billion and can be affected by a number of factors $3.7 billion from payment of the second other than the delivery of operating plans interim dividend from 2011 and the first and normal competition, such as: interim dividend from 2012.
The Companys commitment to its progressive dividend The risk of generic competition following policy was confirmed with the full year loss of patent protection or patent expiry 2012 results announcement.
of one of our products or an at risk launch by a competitor or the launch Simon Lowth of a generic competitor in the same class Chief Financial officer as one of our products, with the potential adverse effects on sales volumes and prices.
For example, in 2012, our performance was affected by generic competition in the US for Seroquel IR and, again in the US, there has been 86 AstraZeneca Annual Report and Form 20-F Information 2012 Overview Strategy Performance Corporate Governance Financial Statements Additional Information The financial performance for the full year 2012 was defined by the loss of exclusivity for several products.
some volume decline of Crestor following Over the longer term, the success of our Core EPS decreased by 9% Reported: the introduction of a large number of R&D is crucial and we devote substantial 12% to $6.41.
Basic EPS was down 29% generic atorvastatin products.
Further resources to this area.
The benets of this Reported: 32% to $4.99.
Basic and details of patent expiries for our key investment are expected to emerge over the Core EPS benefited by $0.37 from two marketed products are included in the long term and there is considerable inherent separate tax-related matters during the Patent expiries section on page 35. uncertainty as to whether and when it will year.
Proceeds from the sale of Nexium The adverse impact on pharmaceutical generate future products.
OTC rights contributed $0.16 to Basic prices as a result of the macroeconomic and Core EPS.
The larger decline in Basic The most significant features of our financial and regulatory environment.
For instance, EPS reects the $1.08 per share benefit results in 2012 are: although there is no direct governmental in 2011 from the sale of Astra Tech and Revenue was down 15% to $27,973 million control on prices in the US, action from higher restructuring costs in 2012, neither Reported: 17%.
federal and individual state programmes of which are included in Core earnings.
Loss of exclusivity on several brands, and health insurance bodies is leading to Dividends paid decreased to most notably Seroquel IR, and the downward pressures on realised prices.
disposals of Astra Tech and Aptium were In other parts of the world, there are a Net share repurchases totalled the key drivers of the revenue decline.
variety of price and volume control $2,206 million 2011: $5,606 million.
Symbicort, Faslodex, Onglyza, Iressa, mechanisms and retrospective rebates On 1 October, the Group announced Brilinta Brilique and Seroquel XR delivered based on sales levels that are imposed the suspension of its share repurchase aggregate CER revenue growth of by governments.
$600 million for the full year.
The timings of new product launches, Total restructuring costs associated with Emerging Markets revenue increased which can be inuenced by national the global programme to reshape the cost by 4% Reported: unchanged.
regulators, and the risk that such new base of the business were $1,558 million Core operating profit was down 18% products do not succeed as anticipated, in 2012.
Total costs to date for this third Reported: 21% to $10,430 million, together with the rate of sales growth and phase of restructuring, comprised of driven by lower revenues and lower Core costs following new product launches.
initiatives across the supply chain, SG&A gross margin, partially offset by reduced Currency uctuations.
Our functional and R&D, amount to $1,819 million.
and reporting currency is the US dollar, This brings the total restructuring costs Reported operating profit was down but we have substantial exposures charged to 31 December, since the start 34% Reported: 36% to $8,148 million.
to other currencies, in particular the of our restructuring programme in 2007, Core operating margin of 37.3% of euro, Japanese yen, pound sterling to $6,427 million.
Most of the remaining revenue was down 1.6 percentage and Swedish krona.
costs of approximately $300 million for the points at CER.
Reported operating Macro factors such as greater demand third phase of our restructuring will be margin was 29.1% of revenue.
from an ageing population and increasing taken in 2013. requirements of Emerging Markets.
AstraZeneca Annual Report and Form 20-F Information 2012 87 Performance | Financial Review Measuring performance quality of the business.
Core pre-R&D on our Reported financial information, The following measures are referred to in operating margin is a non-GAAP both as a whole and in respect of specic this Financial Review when reporting on our measure of our Core financial line items.
performance both in absolute terms but performance.
A reconciliation of Core more often in comparison to earlier years: Core pre-R&D operating margin is our Core pre-R&D operating margin to our Reported performance.
Reported operating margin before Core R&D costs operating profit is provided on the page performance takes into account all the recorded in the year.
This measure reects opposite and page 95. factors including those which we cannot Core operating performance before Prescription volumes and trends for key inuence, principally currency exchange reinvestment in internal R&D.
These measures can represent rates that have affected the results of the real business growth and the progress Management presents these results our business as reected in our Group of individual products better and more externally to meet investors requirements Financial Statements prepared in immediately than invoiced sales.
Core financial accordance with IFRSs as adopted Net funds debt.
This represents our measures are also used internally in the by the EU and as issued by the IASB.
cash and cash equivalents, current management of our business performance, Core financial measures.
These are investments and derivative financial in our budgeting process and when non-GAAP measures because, unlike instruments less interest-bearing loans determining compensation.
Reported performance, they cannot and borrowings.
Core financial measures are non-GAAP be derived directly from the information adjusted measures.
All items for which in the Groups Financial Statements.
CER measures allow us to focus on the Core financial measures are adjusted These measures are adjusted to exclude changes in sales and expenses driven by are included in our Reported financial certain significant items, such as charges volume, prices and cost levels relative to information as they represent actual costs and provisions related to our global the prior period.
Sales and cost growth of our business in the periods presented.
restructuring programmes, amortisation expressed in CER allows management As a result, Core financial measures merely and impairment of the significant to understand the true local movement in allow investors to differentiate between intangibles relating to the acquisition of sales and costs, in order to compare recent different kinds of costs and they should not MedImmune in 2007, the amortisation trends and relative return on investment.
You should also refer and impairment of the significant CER growth rates can be used to analyse to our Reported financial information in the intangibles relating to our exit arrangements sales in a number of ways but, most often, 2012 Reported operating profit table on the with Merck in the US and other specified we consider CER growth by products and page opposite, our reconciliation of Core items.
In determining the adjustments groups of products, and by countries and financial measures to Reported financial to arrive at the Core result, we use a regions.
CER sales growth can be further information in the Reconciliation of set of established principles relating to analysed into the impact of sales volumes Reported results to Core results table on the nature and materiality of individual and selling price.
Similarly, CER cost the page opposite, and to the Results of items or groups of items, excluding, for growth helps us to focus on the real local operations summary analysis of year to example, events which i are outside change in costs so that we can manage 31 December 2011 section from page 95 of the normal course of business, ii the cost base effectively.
for our discussion of comparative Reported are incurred in a pattern that is unrelated We believe that disclosing Core financial growth measures that reect all factors that to the trends in the underlying financial and growth measures in addition to our affect our business.
Our determination of performance of our ongoing business, Reported financial information enhances non-GAAP measures, and our presentation or iii are related to major acquisitions, investors ability to evaluate and analyse of them within this financial information, to ensure that investors ability to evaluate the underlying financial performance of may differ from similarly titled non-GAAP and analyse the underlying financial our ongoing business and the related key measures of other companies.
performance of our ongoing business is business drivers.
See the 2012 Reconciliation With effect from the first quarter results to our Reported financial information in of Reported results to Core results table of 2013, we will update our denition of order to show Core financial measures on the page opposite for a reconciliation Core financial measures to exclude all illustrate clearly, and on a year-on-year or of Reported to Core performance.
intangible asset amortisation charges and period-by-period basis, the impact upon Constant exchange rate CER growth impairments, except those for IS-related our performance caused by factors such rates.
These are also non-GAAP intangibles.
Further details of this change as changes in sales and expenses driven measures.
These measures remove are included in the Revised Core financial by volume, prices and cost levels relative the effects of currency movements measures section of this Financial Review to such prior years or periods.
by retranslating the current years from page 97.
With the exception of the As shown in the 2012 Reconciliation of performance at previous years exchange numbers detailed on page 98, all other Reported results to Core results table rates and adjusting for other exchange references to Core in this Annual Report on the page opposite, our reconciliation effects, including hedging.
A reconciliation are calculated using our current denition of the Reported results adjusted for of Reported financial information to Core of Core.
the impact of currency movements is financial measures includes a breakdown The SET retains strategic management of provided in the 2012 Reported operating of the items for which our Reported the costs excluded from Reported financial profit table on the page opposite.
financial information is adjusted and a information in arriving at Core financial Gross and operating profit margin further breakdown by specic line item as measures, tracking their impact on Reported percentages, and Core pre-R&D such items are reected in our Reported operating profit and EPS, with operational operating margin.
These measures set income statement.
This illustrates the management being delegated on a out the progression of key performance significant items that are excluded from case-by-case basis to ensure clear margins and illustrate the overall Core financial measures and their impact accountability and consistency for each cost category.
88 AstraZeneca Annual Report and Form 20-F Information 2012 Overview Strategy Performance Corporate Governance Financial Statements Additional Information Results of operations summary analysis of year to 31 December 2012 2012 Reported operating profit 2012 2011 Percentage of sales 2012 compared with 2011 Growth due to CER exchange Reported Reported CER Reported Reported growth effects Reported 2012 2011 growth growth $m $m $m $m % % % % Revenue 27,973 4,965 653 33,591 15 17 Cost of sales 5,393 528 105 6,026 19.3 17.9 9 11 Gross profit 22,580 4,437 548 27,565 80.7 82.1 16 18 Distribution costs 320 16 10 346 1.1 1.0 5 8 Research and development 5,243 208 72 5,523 18.8 16.5 4 5 Selling, general and administrative costs 9,839 1,134 188 11,161 35.2 33.2 10 12 profit on disposal of Astra Tech 1,483 1,483 4.4 n a n a Other operating income and expense 970 211 18 777 3.5 2.3 27 25 Operating profit 8,148 4,351 296 12,795 29.1 38.1 34 36 Net finance expense 430 428 profit before tax 7,718 12,367 Taxation 1,391 2,351 profit for the period 6,327 10,016 Basic earnings per share $ 4.99 7.33 2012 Core operating results 2012 2011 2012 compared with 2011 Growth due to Total CER exchange CER Core Core growth effects Core growth growth $m $m $m $m % % Gross profit 22,716 4,355 548 27,619 16 18 Gross margin % 81.2% 82.2% Distribution costs 320 16 10 346 5 8 Research and development 4,452 533 48 5,033 11 12 Selling, general and administrative costs 8,541 1,207 170 9,918 12 14 Other operating income and expense 1,027 200 18 845 24 22 Operating profit 10,430 2,399 338 13,167 18 21 Operating margin % 37.3% 39.2% Net finance expense 430 428 profit before tax 10,000 12,739 Taxation 1,885 2,797 profit for the period 8,115 9,942 Basic earnings per share $ 6.41 7.28 2012 Reconciliation of Reported results to Core results Merck & MedImmune Legal 2012 Restructuring Intangible provisions 2012 Reported costs Amortisation impairments and other Core $m $m $m $m $m $m Gross profit 22,580 136 22,716 Distribution costs 320 320 Research and development 5,243 791 4,452 Selling, general and administrative costs 9,839 631 534 133 8,541 Other operating income and expense 970 57 1,027 Operating profit 8,148 1,558 591 133 10,430 Add back: Research and development 5,243 791 4,452 Pre-R&D operating profit 13,391 767 591 133 14,882 Pre-R&D operating margin % 47.9% 53.2% Net finance expense 430 430 profit before tax 7,718 1,558 591 133 10,000 Taxation 1,391 375 87 32 1,885 profit for the period 6,327 1,183 504 101 8,115 Basic earnings per share $ 4.99 0.94 0.40 0.08 6.41 AstraZeneca Annual Report and Form 20-F Information 2012 89 Performance | Financial Review Revenue decreased by 15% on a CER Core pre-R&D operating margin was 53.2%, 32%.
The larger declines compared with basis and 17% on a Reported basis.
down 0.9 percentage points Reported: the respective Core financial measures More than 13 percentage points of the 1.0 percentage points, as the benefit from are the result of the $1,483 million benefit decline at CER approximately $4.5 billion higher Core other income was more than to Reported other income in 2011 from was related to loss of exclusivity on several offset by higher Core cost of sales and Core the sale of Astra Tech, together with higher brands in the portfolio.
Seroquel IR revenues SG&A costs as a percentage of revenue.
restructuring and amortisation costs in 2012 declined by $3 billion and regional losses of compared with the prior year.
Core operating profit was $10,430 million, exclusivity for Atacand, Nexium and Crestor a decrease of 18% Reported: 21%.
Net finance expense was $430 million, in combined for a further negative impact of Core operating margin declined by line with the $428 million expense recorded more than $1 billion.
The disposals of Astra 1.6 percentage points Reported: in 2011.
Net fair value losses on long-term Tech and Aptium accounted for a further 1.9 percentage points to 37.3% as debt and derivatives were $10 million for the decrease of $562 million, or approximately a result of an unfavourable impact from year, versus $4 million gains in 2011.
This 1.7 percentage points of the year-on-year lower Core gross margin combined with was partially offset by reduced net finance revenue change at CER.
Disruptions to higher Core R&D and SG&A costs as a cost on the Groups pension schemes.
our supply chain, from the implementation percentage of revenue, being only partially The Reported taxation charge of $1,391 of an enterprise resource planning IT mitigated by the increased Core other million 2011: $2,351 million consists of system in our plant in Sweden early in the income for the year.
a current tax charge of $1,682 million 2011: year, negatively impacted revenues by Core EPS was $6.41, down 9% Reported: $2,578 million and a credit arising from approximately 1%.
12%, lower than the decline in Core movements on deferred tax of $291 million Revenue in the US was down 21% operating profit as a result of the benets 2011: $227 million.
The current year tax Reported: 21% with revenue in the from net share repurchases and a lower charge includes a prior period current tax Rest of World down 11% Reported: 14%.
Emerging Markets sales increased by 4% Reported: at.
Further details of our sales Pre-tax adjustments to arrive at Core The Reported tax rate for the year was performance are contained in the Therapy amounted to $2,282 million in 2012 18.0% 2011: 19.0%.
The Reported tax rate for the year benefited from a $230 Area Review from page 50 and the 2011: $372 million.
Excluded from million adjustment to deferred tax balances Geographical Review from page 70.
Core results were: following substantive enactment in 2012 Core gross margin of 81.2% decreased Restructuring costs totalling $1,558 million of a reduction in the Swedish corporation 0.9 percentage points Reported: 1.0 2011: $1,161 million, incurred as the tax rate from 26.3% to 22%, which is percentage points.
In 2012, benets from Group commenced the third phase of effective 1 January 2013, and a $240 million the absence of the lower margin businesses restructuring announced in February adjustment in respect of prior periods of Astra Tech and Aptium, and from lower 2012. following the favourable settlement of a net expense related to our accounting Amortisation totalling $591 million 2011: transfer pricing matter.
Excluding these for the amendments to the Merck exit $537 million relating to assets capitalised items, the Reported tax rate for the year arrangements as detailed in Note 9 as part of the MedImmune acquisition would have been 24.1%: this tax rate is to the Financial Statements from page and the Merck exit arrangements, the applied to the taxable Core adjustments to 159, were more than offset by an increase driven by the additional operating profit, resulting in a Core tax rate unfavourable impact from product mix.
amortisation arising from the amendment for the year of 18.9%.
The Reported tax rate Core gross margin in 2011 benefited to the Merck exit arrangements during for last year benefited from a non-taxable from a $131 million settlement of a royalty 2012, as detailed in Note 9 to the Financial gain on the disposal of Astra Tech and a dispute with PDL Biopharma Inc.
Statements from page 159. favourable adjustment to tax provisions of $72 million 2011: $135 million of legal $520 million following the announcement Core R&D expenditure was $4,452 million, provision charges in respect of ongoing in March 2011 that HM Revenue & Customs 11% lower than last year Reported: 12%.
Seroquel franchise legal matters, Average in the UK and the US Internal Revenue Higher costs from new spending on Wholesale Price litigation in the US, the Service had agreed the terms of an Advance in-licensed, acquired or partnered projects, Toprol-XL anti-trust litigation and Nexium Pricing Agreement regarding transfer including $151 million relating to Amylin, commercial litigation.
In line with prior pricing arrangements for AstraZenecas US Ardea and Amgen, were more than offset years these have been excluded from our business for the period from 2002 to the by lower intangible impairments in 2012 Core performance and full details of these end of 2014 and a related valuation matter.
of $186 million compared with 2011 matters are included in Note 25 to the Excluding these benets, the Reported tax impairments of $527 million, a reduction Financial Statements from page 184. rate for 2011 was 26.4%.
of $341 million, and reduced spend $61 million 2011: $nil of acquisitionand on projects.
transaction-related expenses in relation Total comprehensive income for the year Core SG&A costs of $8,541 million were to our Ardea and new BMS collaboration decreased by $3,065 million from 2011 12% lower than in 2011 Reported: 14%, arrangements.
Further details of these to $6,405 million.
This was driven by the as a result of spending discipline, partially transactions are included in Note 9 and decrease in profit for the year of $3,689 offset by amortisation expense related Note 22 to the Financial Statements.
million, partially offset by an increase of to the expansion of our diabetes alliance In 2011, the profit on sale of our subsidiary $624 million in other comprehensive with BMS and increased promotional Astra Tech of $1,483 million was also income, which was principally due to the costs in Emerging Markets.
The excise fee excluded from Core results.
Further non-recurrence in 2012 of $741 million imposed by the enactment of US healthcare details of this disposal are included of actuarial losses recorded in 2011 on reform measures amounted to 2.8% 2011: in Note 22 to the Financial Statements our dened benefit schemes, arising 2.1% of Core SG&A expense for the year.
on page 173. from lower discount rates applied to our long-term pension obligations reecting Core other income of $1,027 million was Reported operating profit was down 34% external market conditions.
$182 million higher Reported growth than Reported: 36% at $8,148 million.
Reported the previous year principally as a result of EPS was $4.99, down 29% Reported: $250 million income from an agreement with Pzer for OTC rights for Nexium.
90 AstraZeneca Annual Report and Form 20-F Information 2012 Overview Strategy Performance Corporate Governance Financial Statements Additional Information Cash ow and liquidity 2012 All data in this section is on a Reported basis.
Summary cash ows 2012 2011 2010 $m $m $m Net funds brought forward at 1 January 2,849 3,653 535 Earnings before interest, tax, depreciation, amortisation and impairment EBITDA 10,666 15,345 14,235 profit on disposal of Astra Tech 1,483 EBITDA before profit on disposal of Astra Tech 10,666 13,862 14,235 Movement in working capital and short-term provisions 706 897 82 Tax paid 2,043 3,999 2,533 Interest paid 545 548 641 Non-cash and other movements 424 597 463 Net cash available from operating activities 6,948 7,821 10,680 Purchase of intangibles net 3,947 458 1,180 Other capital expenditure net 473 737 708 Acquisitions of business operations 1,187 348 Net cash received on disposal of Astra Tech 1,772 Investments 5,607 577 2,236 Dividends 3,665 3,764 3,361 Net share repurchases 2,206 5,606 2,110 Distributions 5,871 9,370 5,471 Other movements 312 168 145 Net debt funds carried forward at 31 December 1,369 2,849 3,653 Net debt funds reconciliation 2012 2011 2010 $m $m $m Cash and cash equivalents 7,701 7,571 11,068 Short-term investments 823 4,248 1,482 Net derivative financial instruments 417 358 325 Cash, short-term investments and derivatives 8,941 12,177 12,875 Overdraft and short-term borrowings 879 221 125 Finance leases 84 Current instalments of loan 1,769 Loans due after one year 9,347 7,338 9,097 Loans and borrowings 10,310 9,328 9,222 Net debt funds 1,369 2,849 3,653 Net cash distributions to shareholders tranches: $1 billion maturing in 2019 with a Cash generated from operating activities decreased from $9,370 million in 2011 coupon of 1.95% and $1 billion maturing in was $6,948 million in the year to 31 December 2012, compared with $7,821 to $5,871 million in 2012, the reduction 2042 with a coupon of 4.00%.
The decrease of $873 million being driven by the suspension of our of $1,980 million from the issue were used to is primarily driven by lower operating profits, share repurchase programme in October.
repay a $1.75 billion bond with a coupon of offset by lower tax payments.
Included in net cash distributions to 5.40% maturing in September 2012 and for shareholders are dividend payments general corporate purposes.
Investment cash outows of $5,607 million of $3,665 million 2011: $3,764 million.
Net debt was $1,369 million at the end include the purchases of Ardea $1,187 of the year, a decrease from net funds million and intangible assets associated At 31 December 2012, outstanding gross of $2,849 million at the end of 2011, with our collaboration with BMS on Amylin debt interest-bearing loans and borrowings a movement of $4,218 million during the $3,358 million.
The 2011 investment cash was $10,310 million 2011: $9,328 million.
year as a result of the net cash outow inow of $577 million benefited from the sale Of this gross debt, $901 million is due within described above.
Further details one year, including $774 million of commercial of the Ardea acquisition and Astra Tech paper borrowings 2011: $nil with various Off-balance sheet transactions and disposal are included in Note 22 to the short-term maturities all within 90 days.
In commitments Financial Statements from page 173.
Our 2011, amounts due within one year included We have no off-balance sheet arrangements Amylin transaction is detailed in Note 9 $1,769 million relating to current instalments and our derivative activities are nonto the Financial Statements on page 161. of loans.
The table below sets out our During September, the Company issued minimum contractual obligations at the $2 billion of new long-term debt in two year end.
Payments due by period Less than Over 2012 2011 1 year 1-3 years 3-5 years 5 years Total Total $m $m $m $m $m $m 1 Bank loans and other borrowings 1,365 2,649 2,536 10,766 17,316 15,515 Finance leases 23 46 32 101 Operating leases 102 140 83 109 434 392 Contracted capital expenditure 245 245 190 Total 1,735 2,835 2,651 10,875 18,096 16,097 1 Bank loans and other borrowings include interest charges payable in the period, as detailed in Note 23 to the Financial Statements on page 175.
AstraZeneca Annual Report and Form 20-F Information 2012 91 Performance | Financial Review Financial position 2012 All data in this section is on a Reported basis.
The decrease in rebates and in net assets is broadly as a result of the million to $5,696 million in line with lower chargebacks is principally driven by the Group profit of $6,327 million, offset by revenues in 2012. reduction in US revenues recorded in 2012. dividends of $3,619 million and net share Further details of the movements on rebates Included within trade receivables is repurchases of $2,206 million.
and chargebacks are included from page 99. approximately $420 million of net Property, plant and equipment receivables, representing 7% of our The reduction in provisions of $518 million Property, plant and equipment decreased trade receivables, due from customers in 2012 includes $1,096 million of additional by $336 million to $6,089 million.
Additions in the eurozone countries of Spain, Italy, charges recorded in the year, offset by of $772 million 2011: $807 million were Portugal and Greece Spain: $120 million: $1,476 million of cash payments.
Included offset by depreciation of $1,023 million Italy: $205 million: Portugal: $30 million: within the $1,096 million of charges for 2011: $1,086 million and disposals and Greece: $65 million.
Within this balance the year is $873 million for our global of $224 million 2011: $233 million.
is approximately $130 million of overdue restructuring initiative and $90 million in government trade receivables.
In light of respect of legal charges.
Cash payments Goodwill and intangible assets current market conditions, debts within of $1,476 million include a reduction in our The Groups goodwill of $9,898 million these eurozone countries have been subject Seroquel franchise-related provisions of 2011: $9,862 million principally arose on to enhanced monitoring and scrutiny by $427 million, following release of monies the acquisition of MedImmune in 2007 the Group.
Our bad debt provisioning from our settlement funds as detailed and the restructuring of our US joint venture against these debts reects our current above, and $853 million for our global with Merck in 1998.
Goodwill of $30 million estimate of the recoverability of these restructuring programme.
Further details arising on our acquisition of Ardea, as balances based on consideration of a of the charges made against our provisions detailed in Note 22 to the Financial number of factors such as the status of are contained in Notes 17 and 25 to the Statements on page 173, was capitalised current negotiations, past payment history Financial Statements.
in 2012. and the budget constraints of individual Tax payable and receivable Intangible assets amounted to $16,448 countries.
In 2012, our revenue from these Net income tax payable has decreased million at 31 December 2012 2011: $10,980 four countries was $876 million Italy, by $275 million to $2,059 million, principally million.
Intangible asset additions were $510 million Spain, $241 million Greece due to the settlement of a transfer pricing $6,916 million in 2012 2011: $442 million, and $168 million Portugal.
matter as detailed in Note 4 to the Financial including $1,464 million arising on the Other receivables decreased by $402 Statements from page 152.
Our tax acquisition of Ardea, $3,358 million arising million to $835 million as a result of monies receivable balance of $803 million from the expansion of our diabetes alliance being released from externally held comprises tax owing to AstraZeneca with BMS and $1,475 million in connection settlement funds in relation to Seroquel from certain governments expected to be with our Merck arrangements.
Prepayments and received on settlements of transfer pricing in the year was $1,296 million 2011: $911 accrued income increased by $563 million audits and disputes see Note 25 to the million and impairments totalled $199 million driven, principally, by an increase in Financial Statements on page 189 and 2011: $553 million.
Further details of prepayments related to our Amylin cash tax timing differences.
Net deferred our additions to intangible assets, and transaction see Note 9 to the Financial tax liabilities increased by $244 million impairments recorded, are included in Note Statements on page 161. in the year.
9 to the Financial Statements from page 159.
Trade and other payables increased by Retirement benefit obligations $862 million in 2012 to $10,222 million, with Net retirement benefit obligations decreased increases in accruals of $1,323 million due by $409 million, driven by an additional lump to our Merck exit commitments, as detailed sum payment made into the UK dened in Note 9 to the Financial Statements from benefit scheme in 2012. page 161, being offset by a decrease 92 AstraZeneca Annual Report and Form 20-F Information 2012 Overview Strategy Performance Corporate Governance Financial Statements Additional Information In recent years the Group has undertaken partners may not become payable due Amylins portfolio of diabetes products.
several initiatives to reduce its net pension to the inherent uncertainty in achieving Amylin, a wholly owned subsidiary of obligation exposure.
For the UK dened the development and revenue milestones BMS, is a biopharmaceutical company benefit pension scheme, which represents linked to the future payments.
As part of dedicated to the discovery, development AstraZenecas largest dened benefit our overall externalisation strategy, we may and commercialisation of innovative scheme, these initiatives have included enter into further collaboration projects medicines for patients with diabetes agreeing funding principles for cash in the future that may include milestone and other metabolic diseases.
Amylins contributions to be paid to the UK pension payments and, therefore, as certain primary focus is on the research, scheme to target a level of assets in excess milestone payments fail to crystallise due to, development and commercialisation of the current expected cost of providing for example, development not proceeding, of a franchise of GLP-1 agonists for benets, and, in 2010, amendments to the they may be replaced by potential payments the treatment of Type 2 diabetes.
scheme to freeze pensionable pay at 30 under new collaborations.
The portfolio of collaboration products June 2010 levels.
In addition to the cash includes Byetta exenatide injection and Investments, divestments contributions to be paid into the UK pension Bydureon exenatide extended-release and capital expenditure scheme, AstraZeneca makes contributions for injectable suspension exenatide As detailed earlier in the Research to an escrow account which is held outside 2mg powder and solvent for prolonged and Development section from page the pension scheme.
The escrow account release suspension for injection that 30, AstraZeneca views collaborations, assets are payable to the fund in agreed are approved for use in both the US including externalisation arrangements circumstances, for example, in the event of and Europe, Symlin pramlinitide acetate in the eld of R&D, as a crucial element AstraZeneca and the pension fund trustee injection that is approved for use in the of the development of our business.
agreeing on a change to the current US, and metreleptin, a leptin analogue The Group has completed over 130 long-term investment strategy.
currently under review at the FDA major externalisation transactions over for the treatment of diabetes and or AstraZeneca has agreed to fund the UK the past three years, two of which were  in patients with dened benefit scheme shortfall by making accounted for as business acquisitions rare forms of inherited or acquired lump sum payments totalling 715 million under IFRS 3 Business Combinations, lipodystrophy.
The first of these lump sum being the acquisition of Ardea in 2012 the alliance for a total consideration of payments of 180 million $278 million was for $1.3 billion and Novexel in 2010 for $3.7 billion.
This includes an amount paid into the pension scheme from the $0.5 billion, and all others were strategic of $135 million relating to an option escrow account in December 2011.
Further of AstraZeneca contained in the further 300 million $463 million was paid details of our business acquisitions collaboration agreement to acquire into the pension scheme during January and disposals in the past three years certain additional governance rights in 2012 and the balance will be paid in due are contained in Note 22 to the Financial respect of the collaboration.
In 2011, 132 million $213 million Statements from page 173.
Details of notied BMS of its decision to exercise was paid into the escrow account and a our significant externalisation transactions the option in August and the balance further 230 million $355 million was paid are given below: of $135 million will be payable once in during January 2012.
At 31 December applicable anti-trust and competition 2012, 462 million $748 million escrow fund In January 2007, AstraZeneca signed approvals are received by AstraZeneca.
assets are included within other investments an exclusive co-development and The Group expects to make this payment co-promotion agreement with BMS for as detailed in Note 10 to the Financial in the first half of 2013. profits and losses the development and commercialisation Statements on page 163. arising from the collaboration will be of Onglyza, a DPP-IV and Forxiga, a In 2012, approximately 97% of the Groups shared equally.
Further details of this selective sodium-glucose co-transporter obligations were concentrated in the UK, collaboration and our accounting 2 SGLT2 inhibitor, both for the treatment the US, Sweden and Germany.
Further treatment for this arrangement are of Type 2 diabetes.
The agreement is details of the Groups pension schemes included in Note 9 to the Financial global with the exception of Japan for are included in Note 18 to the Financial Statements on page 161.
Under each agreement, the Statements from page 167.
In April 2012, AstraZeneca announced two companies jointly develop the clinical an agreement to jointly develop and and marketing strategy and share Commitments and contingencies commercialise five monoclonal antibodies development and commercialisation The Group has commitments and from Amgens clinical inammation expenses on a global basis.
To date, contingencies which are accounted for in portfolio: AMG 139, AMG 157, AMG 181, AstraZeneca has made upfront and accordance with the accounting policies AMG 557 and brodalumab AMG 827. milestone payments totalling $300 million described in the Financial Statements in the Under the terms of the agreement, for Onglyza and $170 million for Forxiga, Group Accounting Policies section from AstraZeneca made a $50 million upfront will make a further payment of $80 million page 146.
The Group also has taxation payment and the companies share contingencies.
These are described in the for Forxiga in early 2013, and may make both costs and profits.
Approximately Taxation section in the Critical accounting future milestone payments of up to 65% of costs for the 2012 to 2014 policies and estimates section on page 99 $150 million on Forxiga contingent on period will be funded by AstraZeneca.
and in Note 25 to the Financial Statements achievement of regulatory milestones Thereafter, the companies will split from page 189. and launch in key markets.
In addition, AstraZeneca launch, profits and losses globally Research and development will make milestone payments to a are shared equally and an additional collaboration payments maximum of $30 million up to launch.
$300 million of sales-related payments Details of future potential R&D collaboration On commercialisation, Amgen will retain for each product may be triggered payments are also included in Note 25 a low single-digit royalty for brodalumab based on worldwide sales success.
to the Financial Statements from page 183. and a mid-single-digit royalty for the rest In August, AstraZeneca expanded its As detailed in Note 25 to the Financial of the portfolio after which the companies diabetes alliance with BMS to incorporate Statements, payments to our collaboration will share profits equally.
The Group determines the above Capitalisation costs.
With the adoption of new denitions externalisation transactions to be significant The total number of shares in issue at of Core financial measures, as detailed using a range of factors.
We look at the 31 December 2012 was 1,247 million.
from page 97, the dividend cover target specic circumstances of the individual 12.2 million Ordinary Shares were issued in is now two times based on Core earnings externalisation arrangement and apply consideration of share option exercises for under the new denition.
In the context several quantitative and qualitative criteria.
Share repurchases of the earnings uctuations that are to be Because we consider our externalisation amounted to 57.8 million Ordinary Shares expected as the Groups revenue base strategy to be an extension of our R&D at a cost of $2,635 million.
Shareholders transitions through this period of exclusivity strategy, the expected total value of equity increased by $491 million to $23,737 losses and new product launches, the development payments under the million at the year end.
Non-controlling Board recognises that dividend cover in transaction and its proportion of our annual interests decreased to $215 million 2011: any year is likely to vary from the two times R&D spend, both of which are proxies for $226 million.
target level through the investment cycle.
overall R&D effort and cost, are important Dividend and share repurchases In setting the distribution policy and the elements of the signicance determination.
The Board has recommended a second overall financial strategy, the Boards Other quantitative criteria we apply include, interim dividend of $1.90 120.5 pence, aim is to continue to strike a balance without limitation, expected levels of future 12.08 SEK to be paid on 18 March 2013. between the interests of the business, sales, the possible value of milestone This brings the full year dividend to $2.80 our financial creditors and our shareholders.
payments and the resources used for 178.6 pence, 18.34 SEK.
After providing for business investment, commercialisation activities for example, funding the progressive dividend policy the number of staff.
Qualitative factors we This dividend is consistent with the and meeting our debt service obligations, consider include, without limitation, new progressive dividend policy, by which the the Board will keep under review the market developments, new territories, new Board intends to maintain or grow the opportunity to return cash in excess areas of research and strategic implications.
In adopting this policy, of these requirements to shareholders the Board recognised that some earnings In aggregate, payments capitalised under through periodic share repurchases.
uctuations are to be expected as the the Groups externalisation arrangements, Groups revenue base transitions through Future prospects other than those detailed above, amounted this period of exclusivity losses and new We believe challenging market conditions to $156 million in 2012, $123 million in product launches.
The Boards view is will persist in 2013, including continued 2011 and $337 million in 2010.
The Group that the annual dividend will not just reect government interventions in price.
The recognised other income in respect of the financial performance of a single year revenue impact from the loss of exclusivity other externalisation arrangements totalling taken in isolation, but reect its view of will also continue to affect our performance.
$255 million in 2012, including $250 million the earnings prospects for the Group over In the context of the ongoing update to our of income from an agreement with Pzer the entirety of the investment cycle.
strategy, we have withdrawn the planning for OTC rights for Nexium, $18 million assumptions for revenue and margin in 2011 and $82 million in 2010.
The Company has revised the basis by evolution for the period 2010 to 2014 we which it assesses dividend cover.
We plan to hold previous basis was a dividend cover target a Capital Markets Day in March 2013 of two times ie a payout ratio of 50% based to provide a more detailed exposition on Reported earnings before restructuring of our strategic priorities.
94 AstraZeneca Annual Report and Form 20-F Information 2012 Overview Strategy Performance Corporate Governance Financial Statements Additional Information Results of operations summary analysis of year to 31 December 2011 2011 Reported operating profit 2011 2010 Percentage of sales 2011 compared with 2010 Growth due to CER exchange Reported Reported CER Reported Reported growth effects Reported 2011 2010 growth growth $m $m $m $m % % % % Revenue 33,591 601 923 33,269 2 1 Cost of sales 6,026 625 262 6,389 17.9 19.2 10 6 Gross profit 27,565 24 661 26,880 82.1 80.8 3 Distribution costs 346 3 14 335 1.0 1.0 1 3 Research and development 5,523 15 190 5,318 16.5 16.0 4 Selling, general and administrative costs 11,161 409 307 10,445 33.2 31.4 4 7 profit on disposal of Astra Tech 1,483 1,483 4.4 n a n a Other operating income and expense 777 59 6 712 2.3 2.1 8 9 Operating profit 12,795 1,145 156 11,494 38.1 34.5 10 11 Net finance expense 428 517 profit before tax 12,367 10,977 Taxation 2,351 2,896 profit for the period 10,016 8,081 Basic earnings per share $ 7.33 5.60 2011 Core operating results 2011 2010 2011 compared with 2010 Growth due to Total CER exchange CER Core Core growth effects Core growth growth $m $m $m $m % % Gross profit 27,619 63 658 27,024 2 Gross margin % 82.2% 81.2% Distribution costs 346 3 14 335 1 3 Research and development 5,033 639 175 4,219 15 19 Selling, general and administrative costs 9,918 160 301 9,777 2 1 Other operating income and expense 845 71 6 910 8 7 Operating profit 13,167 610 174 13,603 4 3 Operating margin % 39.2% 40.8% Net finance expense 428 517 profit before tax 12,739 13,086 Taxation 2,797 3,416 profit for the period 9,942 9,670 Basic earnings per share $ 7.28 6.71 2011 Reconciliation of Reported results to Core results Merck & MedImmune profit on 2011 Restructuring Intangible Legal disposal of 2011 Reported costs Amortisation impairments settlements Astra Tech Core $m $m $m $m $m $m $m Gross profit 27,565 54 27,619 Distribution costs 346 346 Research and development 5,523 468 22 5,033 Selling, general and administrative costs 11,161 639 469 135 9,918 profit on disposal of Astra Tech 1,483 1,483 Other operating income and expense 777 68 845 Operating profit 12,795 1,161 537 22 135 1,483 13,167 Add back: Research and development 5,523 468 22 5,033 Pre-R&D operating profit 18,318 693 537 135 1,483 18,200 Pre-R&D operating margin % 54.5% 54.2% Net finance expense 428 428 profit before tax 12,367 1,161 537 22 135 1,483 12,739 Taxation 2,351 306 98 6 36 2,797 profit for the period 10,016 855 439 16 99 1,483 9,942 Basic earnings per share $ 7.33 0.63 0.32 0.01 0.07 1.08 7.28 AstraZeneca Annual Report and Form 20-F Information 2012 95 Performance | Financial Review 2011 revenue increased by 1% on a Core EPS was $7.28 in 2011, up 7% The 2011 Reported taxation charge Reported basis but decreased by 2% on Reported: 9%, with the lower operating of $2,351 million 2010: $2,896 million a CER basis.
As in 2010, revenue benefited profit offset by a lower tax rate, lower net consisted of a current tax charge of from strong growth of Crestor, Symbicort interest as well as the benefit of a lower $2,578 million 2010: $3,435 million and and the Seroquel franchise but was offset average number of shares outstanding.
a credit arising from movements on deferred by lower revenues for Nexium, Arimidex and tax of $227 million 2010: $539 million.
Within Core adjustments for 2011, Seloken Toprol-XL.
Emerging Markets sales The 2011 current year tax charge included a restructuring costs and amortisation growth of 10% in 2011 Reported: 11% and prior period current tax credit of $102 million were broadly in line with 2010.
Non-core Established ROW 4% Reported: 14% was 2010: charge of $370 million.
The Reported intangible impairments and legal provisions offset by a decline in 2011 US sales of 2% tax rate for 2011 was 19.0% 2010: 26.4%.
Reported: 2% and Western Europe of 11% The 2011 Reported tax rate benefited from In 2011, Core adjustments also included Reported: 7%.
Further details of our sales the non-taxable gain on the disposal of the profit on the sale of our dental and performance are contained in the Therapy Astra Tech and an adjustment in respect healthcare subsidiary Astra Tech.
Area Review from page 50 and the of prior periods following the announcement Excluded from 2011 Core results were: Geographical Review from page 70. in March 2011 that HM Revenue & Customs Impairment charges of $22 million in the UK and the US Internal Revenue Core gross margin in 2011 of 82.2% increased 2010: $568 million, arising from Service had agreed the terms of an Advance 1.3 percentage points Reported: 1.0 impairments of assets capitalised as Pricing Agreement regarding transfer pricing percentage points.
The 2011 year-on-year part of the MedImmune acquisition.
arrangements for AstraZenecas US business improvement in the margin was largely due $135 million 2010: $612 million of legal for the period from 2002 to the end of 2014 to the impact of the intangible impairment provision charges in respect of the and a related valuation matter.
Excluding related to lesogaberan on 2010 gross ongoing Seroquel IR product liability these benets, the Reported tax rate for margin and a $131 million benefit from the litigation, Average Wholesale Price 2011 was 26.4%.
settlement of a royalty dispute with PDL litigation in the US and the Toprol-XL Biopharma Inc. in 2011.
Total comprehensive income for 2011 anti-trust litigation.
increased by $1,364 million to $9,470 Core R&D expenditure in 2011 was Restructuring costs totalling $1,161 million million.
This was driven by the increase $5,033 million, 15% higher than 2010 in 2011 2010: $1,202 million, incurred in profit in 2011 of $1,935 million, offset Reported: 19%, driven by higher intangible as the Group continued its previously by a decrease of $571 million in other impairments charged to R&D expenditure announced efficiency programmes.
comprehensive income, principally due in 2011, including $285 million for olaparib Amortisation totalling $537 million to $741 million of actuarial losses on our and $150 million for TC-5214, and late-stage 2010: $518 million relating to assets dened benefit schemes arising from project spend.
capitalised in 2011 as part of the lower discount rates being applied in 2011 MedImmune acquisition and the Merck 2011 Core SG&A costs of $9,918 million to our long-term pension obligations exit arrangements.
were 2% lower than in 2010 Reported: reecting external market conditions.
profit on sale of our subsidiary Astra 1% higher.
Investment in Emerging Tech of $1,483 million.
On 31 August Cash ow and liquidity 2011 Markets and recently launched brands, 2011, we completed the sale of Astra All data in this section is on a Reported basis.
as well as the impact of the US healthcare Tech to DENTSPLY International Inc. reform excise tax were more than offset Cash generated from operating activities for a net cash consideration of $1,772 by operational efficiencies across was $7,821 million in the year to million.
Further details of this disposal Established Markets.
31 December 2011, compared with are included in Note 22 to the Financial $10,680 million in 2010.
The decrease Core other income in 2011 of $845 million Statements on page 173. of $2,859 million was primarily driven was $65 million less than the previous year, by higher tax payments made in 2011, 2011 Reported operating profit was up principally as a result of a higher level of including a net amount of $1.1 billion in 10% at CER Reported: 11% at $12,795 disposal gains in 2010. relation to the Advance Pricing Agreement million, largely as a result of the impact Core pre-R&D operating margin was of the profit on the disposal of Astra Tech.
between the UK and US governments 54.2% in 2011, up 1.0 percentage points Reported EPS was $7.33 in 2011, up 29% tax authorities and the settlement of Reported: 0.7 percentage points, as the Reported: 31%, as a result of the same a related valuation matter, an increase in higher 2011 gross margin was only slightly factors affecting Core EPS along with trade and other receivables and higher offset by lower Core other income and the profit recognised on the disposal contributions made to our UK dened higher SG&A costs as a percentage of Astra Tech.
Net finance expense was $428 million Investment cash inows of $577 million 2011 Core operating profit was in 2011, against $517 million in 2010, due in 2011 included the sale of Astra Tech $13,167 million, a decrease of 4% from to reduced interest payable on lower debt $1,772 million.
Cash outows on the 2010 Reported: 3%.
Core operating balances $46 million and a lower net purchase of tangible xed assets amounted margin declined by 1.2 percentage pension interest expense of $55 million to $839 million in 2011, in line with the points Reported: 1.6 percentage points principally due to increased pension assets previous year.
to 39.2% in 2011 as a result of the higher held by our dened benefit schemes.
Net cash distributions to shareholders R&D spend and lower Core other increased from $5,471 million in 2010 to operating income.
$9,370 million in 2011 through dividend payments of $3,764 million and net share repurchases of $5,606 million.
96 AstraZeneca Annual Report and Form 20-F Information 2012 Overview Strategy Performance Corporate Governance Financial Statements Additional Information At 31 December 2011, outstanding gross Trade and other payables increased by the new denition has been extended debt interest-bearing loans and borrowings $326 million in 2011, driven by increases to provide better clarity of the impact was $9,328 million 2010: $9,222 million.
in accruals of $177 million and rebates and from amortisation and impairment charges Of this gross debt, $1,990 million was due chargebacks of $446 million, offset by a included in Reported results and, in within one year 2010: $125 million.
decrease in other payables of $215 million.
addition, while recognising that non-GAAP The increase in rebates and chargebacks measures differ between companies, Financial position 2011 arose principally from increased managedit will aid comparability of our results All data in this section is on a Reported basis.
care and group purchasing organisation versus our peers.
In 2011, net assets increased by $62 million rebates.
Further details of the movements The items excluded from Core results under to $23,472 million.
The increase in net on rebates and chargebacks are included the existing denition, as disclosed in detail assets as a result of the 2011 Group profit from page 99. on page 88, remain a constituent part of $10,016 million was offset by dividends The movement in provisions of $76 million of the new denition.
The existing denition of $3,752 million and share repurchases in 2011 included $716 million of additional excludes from our Core numbers certain of $6,015 million.
charges recorded in the year, offset by significant items, such as charges and Property, plant and equipment $657 million of cash payments.
Included provisions related to our global restructuring Property, plant and equipment decreased within the $716 million of charges in 2011 programmes, amortisation and impairment by $532 million to $6,425 million in 2011. was $135 million in respect of legal charges of the significant intangibles relating to our Additions of $807 million 2010: $808 million and $450 million for our global restructuring acquisition of MedImmune in 2007 and our were offset by depreciation of $1,068 million initiative.
2011 cash payments of $657 exit arrangements with Merck in the US, 2010: $1,076 million and disposals of $233 million included $377 million against our and other specified items.
In determining the million 2010: $73 million, including $151 ongoing global restructuring initiative and adjustments to arrive at the Core result, we million of assets on the sale of Astra Tech.
$153 million related to legal matters.
use a set of established principles relating to the nature and materiality of individual items Goodwill and intangible assets Tax payable and receivable or groups of items, excluding, for example, Our goodwill of $9,862 million at 31 Net income tax payable in 2011 decreased events which i are outside of the normal December 2011 2010: $9,871 million by $1,521 million to $2,334 million, principally course of business, ii are incurred in a principally arose on the acquisition of due to the payment of a net amount pattern that is unrelated to the trends in MedImmune and the restructuring of of $1.1 billion in relation to the Advance the underlying financial performance of our our US joint venture with Merck in 1998.
Pricing Agreement between the UK ongoing business, or iii are related to major No goodwill was capitalised in 2011. and US governments tax authorities acquisitions, to ensure that investors ability and the settlement of a related valuation Intangible assets amounted to $10,980 to evaluate and analyse the underlying matter.
The tax receivable balance of million at 31 December 2011 2010: financial performance of our ongoing $1,056 million largely comprised tax owing $12,158 million.
Intangible asset additions business is enhanced.
to AstraZeneca from certain governments were $442 million in 2011 2010: $1,791 expected to be received on settlements Adjustments between Reported and million, amortisation was $911 million of transfer pricing audits and disputes.
revised Core performance measures 2010: $810 million and impairments Net deferred tax liabilities reduced by Under the revised denition of Core, our totalled $553 million 2010: $833 million.
Reported performance will be adjusted for: $113 million of intangible assets were disposed of on the sale of Astra Tech Amortisation and impairments Retirement benefit obligations in 2011. of intangible assets.
The denition Net retirement benefit obligations of this item will be updated to include increased by $202 million in 2011, due Intangible asset impairment charges all amortisation and impairment charges to an increase in post-retirement scheme recorded in 2011 included $285 million for intangible assets except for those obligations of $954 million driven by following the termination of development a reduction in the discount rate applied arising on IS-related assets.
Adjusting of olaparib for the maintenance treatment to long-term scheme obligations, reecting for these items removes the volatility of serous ovarian cancer and an impairment present market conditions for corporate when impairments are booked on of $150 million reecting a lower probability bonds, offset by pension fund employer such assets and is intended to provide of success assessment for TC-5214, based contributions made in the year of a better measure of underlying business on the results of the first two of four Phase III $733 million 2010: $469 million.
It will be extended to cover efcacy and tolerability studies.
all amortisation and impairments relating Revised Core financial measures Receivables, payables and provisions to product marketing and distribution As detailed in our announcement of In 2011, trade receivables increased by rights and other intangibles, incorporating 12 November 2012, with effect from $383 million to $6,630 million driven, those already excluded under the current our first quarter results in 2013, the Group principally, by higher gross sales in the denition relating to our acquisition of will update its denition of Core financial US in December 2011 and the way calendar MedImmune and our exit arrangements measures to exclude all intangible asset working days fell at the 2011 year end.
The amortisation and amortisation charges and impairments, Other receivables increased by $566 million impairment of IS-related intangibles except those for IS-related intangibles.
to $1,237 million at 31 December 2011 As intangible assets acquired as a result driven by an increase in our Seroquel of externalisation become an increasing IR-related settlement funds.
proportion of the Groups asset base, AstraZeneca Annual Report and Form 20-F Information 2012 97 Performance | Financial Review are not included in the adjustment, investigations will be excluded from the to be in the ordinary course of business and will remain in Core.
Core measures and the adjustment will will continue to be excluded from Core.
The denition for be stated net of related insurance Tax on adjustments.
The denition for this this item has not been changed.
In the ordinary course of item has not been changed.
The Groups charges arise from the major restructuring business, external legal professional fees, Reported tax rate, adjusted for significant programmes announced by the Group.
including those relating to IP protection one-off items embedded within that rate, Legal charges and other charges.
The costs, and the costs of AstraZenecas is applied to all taxable Core adjustments.
denition for this item has not been in-house legal function will remain in Core.
Reconciliations of Existing Core changed.
Legal payments, charges Professional fees directly attributable to to Revised Core and expenses related to settlements, AstraZenecas significant acquisitions and The adjustments that will be made to our judgments and fines in the context other significant business combination existing Core denition to arrive at our of product liability litigation, anti-trust activity will continue to be excluded from revised Core denition for use from 2013 litigation, patent litigation and government Core.
Other specified items deemed not onwards are detailed in the tables below.
2012 Reconciliation of Existing Core results to Revised Core results Revised Core additional Revised Core adjustments 2012 compared with 2011 2012 Existing 2012 Revised Core Core CER growth Total growth $m page 89 Amortisation Impairments $m % % Revenue 27,973 27,973 15 17 Cost of sales 5,257 325 4,932 Gross profit 22,716 325 23,041 15 17 Distribution costs 320 320 5 8 Research and development 4,452 25 186 4,241 4 5 Selling, general and administrative costs 8,541 152 8,389 13 15 Other operating income and expense 1,027 41 1,068 29 26 Operating profit 10,430 543 186 11,159 17 20 Net finance expense 430 430 profit before tax 10,000 543 186 10,729 18 20 Taxation 1,885 107 45 2,037 profit for the period 8,115 436 141 8,692 15 17 Basic earnings per share $ 6.41 0.35 0.11 6.87 8 11 2011 Reconciliation of Existing Core results to Revised Core results Revised Core additional Revised Core adjustments 2011 compared with 2010 2011 Existing 2011 Revised Core Core CER growth Total growth $m page 95 Amortisation Impairments $m % % Revenue 33,591 33,591 2 1 Cost of sales 5,972 129 5,843 Gross profit 27,619 129 27,748 1 2 Distribution costs 346 346 1 3 Research and development 5,033 27 527 4,479 6 10 Selling, general and administrative costs 9,918 78 4 9,836 2 1 Other operating income and expense 845 845 8 7 Operating profit 13,167 234 531 13,932 2 1 Net finance expense 428 428 profit before tax 12,739 234 531 13,504 1 Taxation 2,797 28 140 2,965 profit for the period 9,942 206 391 10,539 4 5 Basic earnings per share $ 7.28 0.15 0.29 7.72 10 11 98 AstraZeneca Annual Report and Form 20-F Information 2012 Overview Strategy Performance Corporate Governance Financial Statements Additional Information Financial risk management Our capital and risk management objectives Chargebacks, where we enter into Financial risk management policies and policies are described in further detail arrangements under which certain Insurance in Note 23 to the Financial Statements from parties, typically hospitals, the Our risk management processes are page 175 and in the Risk section from page Department of Veterans Affairs, Public described in the Managing risk section 74.
Health Service Covered Entities and the from page 74.
These processes enable us Department of Defense, are able to buy Sensitivity analysis of the Groups exposure to identify risks that can be partly or entirely products from wholesalers at the lower to exchange rate and interest rate movements mitigated through the use of insurance.
prices we have contracted with them.
is also detailed in Note 23 to the Financial We negotiate best available premium rates The chargeback is the difference between Statements from page 175. with insurance providers on the basis of our the price we invoice to the wholesaler Critical accounting policies extensive risk management procedures.
and the contracted price charged by and estimates In the current insurance market, the level the wholesaler.
Chargebacks are paid Our Financial Statements are prepared in of cover is decreasing while premium rates directly to the wholesalers.
accordance with IFRSs as adopted by the are increasing.
Rather than simply paying Regulatory, including Medicaid and other EU adopted IFRS and as issued by the higher premiums for lower cover, we focus federal and state programmes, where we IASB, and the accounting policies employed our insurance resources on the most critical pay rebates based on the specic terms are set out in the Group Accounting Policies areas, or where there is a legal requirement, of agreements with the US Department section in the Financial Statements from and where we can get best value for money.
of Health and Human Services and with page 146.
In applying these policies, we Risks to which we pay particular attention individual states, which include product make estimates and assumptions that affect include business interruption, Directors usage and information on best prices the reported amounts of assets and and Ofcers liability and property damage.
and average market prices benchmarks.
liabilities and disclosure of contingent assets Insurance for product liability has not Contractual, under which entities such as and liabilities.
The actual outcome could been available on commercially acceptable third party managed-care organisations, differ from those estimates.
Some of these terms for several years and the Group has long-term care facilities and group policies require a high level of judgement not held product liability insurance since purchasing organisations are entitled because the areas are especially subjective February 2006. to rebates depending on specified or complex.
We believe that the most critical performance provisions, which vary Taxation accounting policies and significant areas from contract to contract.
Tax risk management forms an integrated of judgement and estimation are in: part of the Groups risk management The effects of these deductions on processes.
Our tax strategy is to manage revenue recognition our US pharmaceuticals revenue and tax risks and tax costs in a manner research and development the movements on US pharmaceuticals consistent with shareholders best impairment testing of goodwill revenue provisions are set out overleaf.
long-term interests, taking into account and intangible assets Accrual assumptions are built up on a both economic and reputational factors.
litigation product-by-product and customer-byWe draw a distinction between tax planning post-retirement benets customer basis, taking into account specic using articial structures and optimising t axation.
contract provisions coupled with expected tax treatment of business transactions, Revenue recognition performance, and are then aggregated into and we engage only in the latter.
Revenue is recorded at the invoiced amount a weighted average rebate accrual rate for Treasury excluding inter-company sales and value each of our products.
Accrual rates are The principal financial risks to which added taxes less movements in estimated reviewed and adjusted on a monthly basis.
the Group is exposed are those arising accruals for rebates and chargebacks given There may be further adjustments when from liquidity, interest rate, foreign currency to managed-care and other customers and actual rebates are invoiced based on and credit.
The Group has a centralised product returns a particular feature in the utilisation information submitted to us treasury function to manage these risks US.
The impact in the rest of the world is not in the case of contractual rebates and in accordance with Board-approved significant.
It is the Groups policy to offer a claims invoices are received in the case policies.
Specically, liquidity risk is credit note for all returns and to destroy all of regulatory rebates and chargebacks.
managed through maintaining access returned stock in all markets.
Cash discounts We believe that we have made reasonable to a number of sources of funding to for prompt payment are also deducted from estimates for future rebates using a similar meet anticipated funding requirements, sales.
Revenue is recognised at the point of methodology to that of previous years.
including committed bank facilities delivery, which is usually when title passes Inevitably, however, such estimates involve and cash resources.
Interest rate risk to the customer either on shipment or on judgements on aggregate future sales is managed through maintaining a debt receipt of goods by the customer depending levels, segment mix and the customers portfolio that is weighted towards xed on local trading terms.
Income from royalties contractual performance.
Accordingly, the Groups and from disposals of IP, brands and product The large increase in managed-care net interest charge is not signicantly lines is included in other operating income.
and group purchasing organisation rebates affected by movements in oating rates Rebates, chargebacks and returns in 2011 was principally driven by the impacts of interest.
We do not currently hedge in the US of the Affordable Care Act.
See page 71 of the impact on earnings and cash ow When invoicing sales in the US, we the Geographical Review for more information.
of changes in exchange rates, with the estimate the rebates and chargebacks that The 2012 adjustment in respect of prior exception of the currency exposure we expect to pay.
These rebates typically years includes renements of the provisions that arises between the booking and arise from sales contracts with third party recorded for the Affordable Care Act.
settlement dates on non-local currency managed-care organisations, hospitals, Cash discounts are offered to customers purchases and sales by subsidiaries long-term care facilities, group purchasing to encourage prompt payment.
Accruals and the external dividend.
Credit risk is organisations and various federal or state are calculated based on historical managed through setting and monitoring programmes Medicaid best price experience and are adjusted to reect credit limits appropriate for the assessed contracts, supplemental rebates etc.
They can be classied as follows: AstraZeneca Annual Report and Form 20-F Information 2012 99 Performance | Financial Review Gross to net sales US Pharmaceuticals 2012 2011 2010 $m $m $m Gross sales 20,747 23,613 22,909 Chargebacks 2,261 1,958 2,075 Regulatory US government and state programmes 1,426 2,293 1,949 Contractual Managed-care and group purchasing organisation rebates 5,597 5,437 4,755 Cash and other discounts 401 452 437 Customer returns 182 72 21 Other 273 276 265 Net sales 10,607 13,125 13,407 Movement in provisions US Pharmaceuticals Brought Carried forward at Adjustment in forward at 1 January Provision for respect of Returns and 31 December 2012 current year prior years payments 2012 $m $m $m $m $m Chargebacks 395 2,296 35 2,343 313 Regulatory US government and state programmes 1,290 1,585 159 1,891 825 Contractual Managed-care and group purchasing organisation rebates 1,600 5,578 19 5,849 1,348 Cash and other discounts 41 401 409 33 Customer returns 121 117 65 92 211 Other 80 273 308 45 Total 3,527 10,250 110 10,892 2,775 Brought Carried forward at Adjustment in forward at 1 January Provision for respect of Returns and 31 December 2011 current year prior years payments 2011 $m $m $m $m $m Chargebacks 523 2,012 54 2,086 395 Regulatory US government and state programmes 1,122 2,364 71 2,125 1,290 Contractual Managed-care and group purchasing organisation rebates 1,194 5,452 15 5,031 1,600 Cash and other discounts 41 452 452 41 Customer returns 133 75 3 84 121 Other 64 276 260 80 Total 3,077 10,631 143 10,038 3,527 Brought Carried forward at Adjustment in forward at 1 January Provision for respect of Returns and 31 December 2010 current year prior years payments 2010 $m $m $m $m $m Chargebacks 396 2,107 32 1,948 523 Regulatory US government and state programmes 775 1,984 35 1,602 1,122 Contractual Managed-care and group purchasing organisation rebates 1,447 4,826 71 5,008 1,194 Cash and other discounts 41 438 1 437 41 Customer returns 177 22 1 65 133 Other 59 269 4 260 64 Total 2,895 9,646 144 9,320 3,077 100 AstraZeneca Annual Report and Form 20-F Information 2012 Overview Strategy Performance Corporate Governance Financial Statements Additional Information Industry practice in the US allows We have distribution service agreements Research and development wholesalers and pharmacies to return with major wholesaler buyers which serve Our business is underpinned by our unused stocks within six months of, and to reduce the speculative purchasing marketed products and development up to 12 months after, shelf-life expiry.
behaviour of the wholesalers and reduce portfolio.
The R&D expenditure on internal The customer is credited for the returned short-term uctuations in the level of activities to generate these products is product by the issuance of a credit note.
We do not offer generally charged to profit in the year Returned products are not exchanged for any incentives to encourage wholesaler that it is incurred.
Purchases of IP and products from inventory and once a return speculative buying and attempt, where product rights to supplement our R&D claim has been determined to be valid possible, to restrict shipments to underlying portfolio are capitalised as intangible and a credit note has been issued to demand when such speculation occurs.
Further details of this policy are the customer, the returned products are included in the Group Accounting Policies Sales of intangible assets destroyed.
At the point of sale in the US, section of our Financial Statements A consequence of charging all internal R&D we estimate the quantity and value of from page 146.
Such intangible assets expenditure to the income statement in the products which may ultimately be returned.
are amortised from the launch of the year in which it is incurred which is normal Our returns accruals in the US are based underlying products and are tested for practice in the pharmaceutical industry on actual experience.
Our estimate is impairment both before and after launch.
is that we own valuable intangible assets based on the preceding 12 months for This policy is in line with practice adopted which are not recorded on the balance established products together with by major pharmaceutical companies.
We also own acquired intangible market-related information, such as assets which are included on the balance Impairment testing of goodwill and estimated stock levels at wholesalers sheet.
As a consequence of regular reviews intangible assets and competitor activity, which we receive of product strategy, from time to time we We have significant investments in goodwill via third party information services.
sell such assets and generate income.
Sales and intangible assets as a result of For newly launched products, we use rates of product lines are often accompanied acquisitions of businesses and purchases based on our experience with similar by an agreement on our part to continue of assets, such as product development products or a pre-determined percentage.
manufacturing the relevant product for a and marketing rights.
For products facing generic competition reasonable period often about two years Details of the estimates and assumptions such as Seroquel IR in the US our while the purchaser constructs its own we make in our annual impairment testing experience is that we usually lose the ability manufacturing facilities.
The contracts of goodwill are included in Note 8 to the to estimate the levels of returns from typically involve the receipt of an upfront Financial Statements on page 158.
No wholesalers with the same degree of payment, which the contract attributes impairment of goodwill was identied.
precision that we can for products still to the sale of the intangible assets, and Impairment reviews have been carried subject to patent protection.
This is because ongoing receipts, which the contract out on all intangible assets that are in we have limited or no insight into a number attributes to the sale of the product we development and not being amortised, of areas: the actual timing of the generic manufacture.
In cases where the transaction all major intangible assets acquired during launch for example, a generic manufacturer has two or more components, we account the year and all intangible assets that have may or may not have produced adequate for the delivered item for example, the had indications of impairment during the pre-launch inventory : the pricing and transfer of title to the intangible asset as year.
Sales forecasts and specic allocated marketing strategy of the competitor: a separate unit of accounting and record costs which have both been subject to the take-up of the generic: and in cases revenue on delivery of that component appropriate senior management sign-off where a generic manufacturer has approval provided that we can make a reasonable are discounted using appropriate rates to launch only one dose size in a market estimate of the fair value of the undelivered based on AstraZenecas risk-adjusted of several dose sizes the likely level of component.
Where the fair market value pre-tax weighted average cost of capital.
switching from one dose to another.
Under of the undelivered component for example, Our weighted average cost of capital our accounting policy, revenue is recognised a manufacturing agreement exceeds the reects factors such as our capital structure only when the amount of the revenue contracted price for that component, we and our costs of debt and equity.
In building can be measured reliably.
Our approach in defer an appropriate element of the upfront to the range of rates used in our internal meeting this condition for products facing consideration and amortise this over the investment appraisal of future projects generic competition will vary from product performance period.
However, where and capital investment decisions, we adjust to product depending on the specic the fair market value of the undelivered our weighted average cost of capital circumstances.
component is equal to or lower than the for other factors, which reect, without contracted price for that component, The closing adjustment in respect of prior limitation, local matters such as risk on we treat the whole of the upfront amount years benefited 2012 net US pharmaceuticals a case-by-case basis.
as being attributable to the delivered revenue by 1.0% 2011: increased revenue intangible assets and recognise that part by 1.1%: 2010: increased revenue by of the revenue upon delivery.
However, taking into account the of the contracted revenue related to the adjustments affecting both the current and undelivered component is allocated to the the prior year, 2011 revenue was reduced by sale of the intangible asset.
This is because 0.3%, and 2010 revenue was not impacted, the contracted revenue relating to the by adjustments between years.
undelivered component is contingent on future events such as sales and so cannot be anticipated.
AstraZeneca Annual Report and Form 20-F Information 2012 101 Performance | Financial Review The majority of our investments in intangible Where it is considered that the Group income statement charge is xed at a set assets and goodwill arose from the is more likely than not to prevail, or in the level or is a set percentage of employees restructuring of the joint venture with Merck rare circumstances where the amount pay.
However, several plans, mainly in the in 1998, the acquisition of MedImmune in of the legal liability cannot be estimated UK which has by far the largest single 2007 and the payments to partially retire reliably, legal costs involved in defending scheme, the US and Sweden, are dened Mercks interests in our products in the the claim are charged to profit as they benefit plans where benets are based on US in 2008 and 2010.
Where it is considered that employees length of service and final salary have included intangible assets acquired the Group has a valid contract which typically averaged over one, three or five through our new collaboration with BMS provides the right to reimbursement years.
The UK and US dened benefit concerning Amylins portfolio of products, from insurance or otherwise of legal schemes were closed to new entrants in our acquisition of Ardea and revised costs and or all or part of any loss incurred 2000.
All new employees in these countries arrangements with Merck concerning or for which a provision has been established are offered dened contribution schemes.
the final step in our exit arrangements.
and we consider recovery to be virtually In applying IAS 19, we recognise all actuarial The Group, including acquisitions, certain, then the best estimate of the gains and losses immediately through is considered a single cash-generating amount expected to be received is reserves.
This methodology results in a less unit for impairment purposes.
We are recognised as an asset.
volatile income statement charge than under satisfied that the carrying values at Assessments as to whether or not to the alternative approach of recognising 31 December 2012 are fully justied recognise provisions or assets and of the actuarial gains and losses over time.
by estimated future cash ows.
The amounts concerned usually involve a series Investment decisions in respect of dened accounting for our arrangements with of complex judgements about future events benefit schemes are based on underlying Merck and our Amylin collaboration and can rely heavily on estimates and actuarial and economic circumstances with with BMS are fully explained in Note 9 assumptions.
AstraZeneca believes that the intention of ensuring that the schemes to the Financial Statements from page the provisions recorded are adequate have sufficient assets to meet liabilities as 159.
Further details of our acquisition based on currently available information they fall due, rather than meeting accounting of Ardea are included in Note 22 to the and that the insurance recoveries recorded requirements.
The trustees follow a strategy Financial Statements from page 173. will be received.
However, given the inherent of awarding mandates to specialist, active Further details of the estimates and uncertainties involved in assessing the investment managers, which results in a assumptions we make in impairment outcomes of these cases and in estimating broad diversication of investment styles testing of intangible assets are included the amount of the potential losses and the and asset classes.
The investment in Note 9 to the Financial Statements.
associated insurance recoveries, we approach is intended to produce less could in future periods incur judgments volatility in the plan asset returns.
Litigation or insurance settlements that could have In the normal course of business, contingent In assessing the discount rate applied a material adverse effect on our results liabilities may arise from product-specic to the obligations, we have used rates in any particular period.
and general legal proceedings, from on AA corporate bonds with durations guarantees or from environmental liabilities The position could change over time, and corresponding to the maturities of those connected with our current or former there can, therefore, be no assurance that obligations, except in Sweden where sites.
Where we believe that potential any losses that result from the outcome of we have used rates on mortgage bonds liabilities have a less than 50% probability any legal proceedings will not exceed the as the market in high quality corporate of crystallising, or where we are unable to amount of the provisions that have been bonds is insufficiently deep.
make a reasonable estimate of the liability, booked in the accounts.
In all cases, the pension costs recorded we treat them as contingent liabilities.
in the Financial Statements are assessed in Although there can be no assurance These are not provided for but are disclosed regarding the outcome of legal proceedings, accordance with the advice of independent in Note 25 to the Financial Statements we do not currently expect them to have qualied actuaries but require the exercise from page 183. a material adverse effect on our financial of significant judgement in relation to position, but they could signicantly affect assumptions for future salary and pension In cases that have been settled or our financial results in any particular period.
increases, long-term price ination and adjudicated, or where quantiable fines and investment returns.
penalties have been assessed and which Post-retirement benets are not subject to appeal or other similar We offer post-retirement benefit plans As detailed in our Accounting Policies forms of relief, or where a loss is probable which cover many of our employees around section of the Financial Statements on page more than 50% assessed probability and the world.
In keeping with local terms and 146, the Group will adopt the amended IAS we are able to make a reasonable estimate conditions, most of these plans are dened 19 from 1 January 2013. of the loss, we indicate the loss absorbed contribution in nature, where the resulting or the amount of the provision accrued.
102 AstraZeneca Annual Report and Form 20-F Information 2012 Overview Strategy Performance Corporate Governance Financial Statements Additional Information Taxation in aggregate, we have covered a significant Accruals for tax contingencies require proportion of each of the key line items management to make judgements and in our Financial Statements.
Each of these estimates in relation to tax audit issues operating units and specialist areas has and exposures.
Amounts accrued are ensured that its relevant processes and based on managements interpretation controls are documented to appropriate of country-specic tax law and the standards, taking into account, in particular, likelihood of settlement.
Tax benets the guidance provided by the SEC.
We are not recognised unless the tax positions have also reviewed the structure and are probable of being sustained.
Once operation of our entity level control considered to be probable, management environment.
This refers to the overarching reviews each material tax benefit to assess control environment, including structure whether a provision should be taken against of reviews, checks and balances that full recognition of the benefit on the basis are essential to the management of of potential settlement through negotiation a well-controlled business.
All such provisions are The Directors have concluded that our included in current liabilities.
Any recorded internal control over financial reporting is exposure to interest on tax liabilities is effective at 31 December 2012 and the provided for in the tax charge.
assessment is set out in the Directors AstraZeneca faces a number of transfer Responsibilities for, and Report on, pricing audits in jurisdictions around Internal Control over Financial Reporting the world and, in some cases, is in on page 140.
KPMG Audit Plc has audited dispute with the tax authorities.
These the effectiveness of our internal control disputes usually result in taxable profits over financial reporting at 31 December being increased in one territory and 2012 and, as noted in the Auditors Reports correspondingly decreased in another.
on the Financial Statements and on Our balance sheet positions for these Internal Control over Financial Reporting matters reect appropriate corresponding Sarbanes-Oxley Act Section 404 relief in the territories affected.
on page 141, their report is unqualied.
Further details of the estimates and assumptions we make in determining our recorded liability for transfer pricing audits and other tax contingencies are included in the Tax section of Note 25 to the Financial Statements on page 189.
Sarbanes-Oxley Act Section 404 As a consequence of our NYSE listing, AstraZeneca is required to comply with those provisions of the Sarbanes-Oxley Act applicable to foreign issuers.
Section 404 of the Sarbanes-Oxley Act requires companies annually to assess and make public statements about the quality and effectiveness of their internal control over financial reporting.
Our approach to the assessment has been to select key transaction and financial reporting processes in our largest operating units and a number of specialist areas, such as financial consolidation and reporting, treasury operations and taxation, so that, AstraZeneca Annual Report and Form 20-F Information 2012 103 Corporate Governance | The value of innovation Innovation means benefits beyond medical advances Our innovation takes many forms which offer significant benets by adding value beyond the medicines themselves.
For example, we are exploring new ways of increasing access to healthcare which take account of the different barriers to healthcare around the world and which are tailored locally to different patient needs.
Our broad market strategy in China means we are expanding the affordability of our medicines to reach an increasing number of physicians and hospitals in communities outside of the most afuent cities, which do not currently have regular access to healthcare and high quality medicines.
104 AstraZeneca Annual Report and Form 20-F Information 2012 Overview Strategy Performance Corporate Governance Financial Statements Additional Information We are active in pioneering public private sector collaborations to identify pragmatic ways of overcoming barriers to healthcare at a global level.
AstraZeneca Annual Report and Form 20-F Information 2012 105
